Sangamo BioSciences and Collaborators to Present Data on ZFP Therapeutic Applications and Developments at Annual Meeting of the American Society of Gene and Cell Therapy

RICHMOND, Calif., May 14, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that data from clinical, preclinical and research-stage programs focused on the development of ZFP Therapeutics^® will be presented at the 17th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT). Fourteen oral and poster presentations, given by Sangamo scientists and their academic collaborators, will detail data from Sangamo's therapeutic and research programs including HIV/AIDS, Huntington's disease and other monogenic diseases, cancer immunotherapy and advancements in the technology including delivery. The meeting will be held in Washington, DC, from May 21-24, 2014.

"We are pleased that the diversity and maturity of Sangamo's ZFP Therapeutic platform will be highlighted at this important gene therapy research forum," said Edward Lanphier, Sangamo's president and CEO. "Data from these clinical and preclinical studies demonstrate the versatility, efficiency and precision of Sangamo's technology as applied to a range of therapeutic applications."

The following presentations are scheduled at the ASGCT Meeting sessions:

HIV/AIDS

• HIV Protected Autologous Zinc Finger Nuclease Driven CCR5 Modified CD4 T-Cells CCR5 (SB-728-T) Reduce HIV Viral Load in CCR5 Δ32 Heterozygote Subjects During Treatment Interruption (TI): Correlates of Effect, and Effect of Cytoxan Pre-Conditioning Regimen; [Abstract #283]; Session: "Results of Preclinical and Clinical Development for Hematological and Immunological Diseases," Thursday, May 22, 2014.
• Cross-Clade Inhibition of HIV on Primary Cells by CXCR4 or CCR5 Fused to the C34 Peptide from gp41 HR2 [Abstract #783];  Session:  "Immune Response to Gene Transfer and Cell Therapy," Saturday, May 24, 2014.

CANCER

• Single Edited T Cells Redirected Towards NY-ESO-1 Ensure Tumor Rejection Without Inducing Xenogeneic GvHD [Abstract #522]; Session:  "Cancer-Immunotherapy," Friday, May 23, 2014.

MONOGENIC DISEASES

• Genetic Correction of Induced Pluripotent Stem Cells from a Wiskott-Aldrich Syndrome Patient Normalizes the Immune Defects [Abstract #94]; Session: "Gene Targeting and Gene Correction,"  Wednesday, May 21, 2014.
• Allele-Specific Repression of Mutant Huntingtin Expression By Engineered Zinc Finger Transcriptional Repressors as a Potential Therapy for Huntington's Disease [Abstract #603]; Session: "Neurological Diseases II," Friday, May 23, 2014.
• Site-Specific Correction of the Sickle Mutation in CD34+ Cells Using Zinc Finger Nucleases [Abstract #753]; Session: "Applications of Genome Editing & Gene Targeting,"  Saturday, May 24, 2014.
• Site-Specific Genome Editing in Human Long-Term Repopulating Hematopoietic Stem Cells for Correction of SCID-X1 [Abstract #754]; Session: "Applications of Genome Editing & Gene Targeting," Saturday, May 24, 2014.
• Restoration of T-Cell Functionality in Classical Scid Mouse By Gene Editing [Abstract #755]; Session: "Applications of Genome Editing & Gene Targeting,"  Saturday, May 24, 2014.

TECHNOLOGY DEVELOPMENT AND OTHER APPLICATIONS

• In Vivo Genome Editing Using Nuclease-Encoding Chemically Modified mRNA, [Abstract #248]; Session: "Genome Editing & Gene Targeting," Thursday, May 22, 2014.
• Genetic Editing To Preclude HLA-A Expression on Hematopoietic Stem Cells -Improving the Chance of Finding an HLA-Matched Donor [Abstract #711]; Session: "Somatic Stem Cells," Friday, May 23, 2014.
• Helper-Dependent Ad5/35 Vectors for ZFN-Mediated Gene Editing in Hematopoietic Stem Cells [Abstract #250]; Session:  "Genome Editing & Gene Targeting," Thursday, May 22, 2014.
• In Vivo Transduction of Mobilized Hematopoietic Stem Cells With an Affinity-Enhanced Ad5/35 Vector [Abstract #461]; Session: "Hematologic & Immunologic Diseases," Thursday, May 22, 2014.
• Combined Preconditioning and In Vivo Chemoselection With 6-Thioguanine for Selection of Genetically Modified Hematopoietic Stem Cells [Abstract #714];  Session: "Somatic Stem Cells," Friday, May 23, 2014.
• KEL-Null Red Blood Cells Derived From In Vitro Differentiation of Zinc-Finger Nuclease-Edited HSCs [Abstract #715];  Session: "Somatic Stem Cells, " Friday, May 23, 2014.

All abstracts for the ASGCT meeting are available online at 2014 ASGCT Annual Meeting Abstracts

About Sangamo
Sangamo BioSciences, Inc. is focused on Engineering Genetic Cures^TM for monogenic and infectious diseases by deploying its novel DNA-binding protein technology platform in therapeutic gene regulation and genome editing. The Company has ongoing Phase 2 clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic^® for the treatment of HIV/AIDS (SB-728-T) and NGF-AAV for Alzheimer's disease (CERE-110). Sangamo's other therapeutic programs are focused on monogenic and rare diseases.  The company has formed a strategic collaboration with Shire International GmbH to develop therapeutics for hemophilia, Huntington's disease and other monogenic diseases, and with Biogen Idec for hemoglobinopathies, such as sickle cell disease and beta-thalassemia. It has also established strategic partnerships with companies in non-therapeutic applications of its technology, including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the Company's website at www.sangamo.com. 
ZFP Therapeutic^® is a registered trademark of Sangamo BioSciences, Inc.

Logo - http://photos.prnewswire.com/prnh/20130102/SF35903LOGO

SOURCE Sangamo BioSciences, Inc.